Establishing a Framework for Health Equity
The ASPIRE Health Equity Working Group seeks to better understand the consequences of differential treatment and identify opportunities to apply practical, effective, systematic solutions that move the amyloidosis community toward health equity.
Current Focus
The group is initiating a trended case study analysis of AL patients and Female ATTR patient experiences across different geographical regions in the United States.
Working Group Members
Corporate Members:
Working Group Co-Chair & ESC Member:
JeShaune Jackson, Director, Strategic Alliances & Patient Advocacy, BridgeBio
ESC Member:
Nisith Kumar, Director, Global Medical Affairs, TTR Amyloidosis, Pfizer
Courtney Ijeoma, PharmD, Associate Director, Medical Science Liaison, Alnylam Pharmaceuticals
Victoria Sanjurjo, MD, PhD, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc
Tessa Field, MS, CGC, Sr. Director, Global Patient Advocacy Lead, Intellia Therapeutics
Other Members:
Robert Gibson
Director, Special Projects, Amyloidosis Support Groups Inc
Accomplishments
The Health Equity Working Group completed a study to better understand the experiences of Black amyloidosis patients who live or work in the Greater Cincinnati Area. The Working Group is currently developing a manuscript to share key findings.
Other Working Groups
Contact
To learn more please contact Megan Glynn, Senior Program Manager for ASPIRE, at mglynn@arci.org.
